Interdigitating dendritic cell tumor with breast and cervical lymph-node involvement: a case report and review of the literature

Uluoglu O., Akyurek N., Uner A., Coskun U., Ozdemir A., Gokcora N.

VIRCHOWS ARCHIV, vol.446, no.5, pp.546-554, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 446 Issue: 5
  • Publication Date: 2005
  • Doi Number: 10.1007/s00428-005-1209-3
  • Journal Name: VIRCHOWS ARCHIV
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.546-554
  • Keywords: interdigitating dendritic cell tumor, breast, prognosis, immunohistochemistry, RETICULUM CELLS, SARCOMA, NEOPLASMS, MALIGNANCIES, PHENOTYPE, INTESTINE, FEATURES, LIGHT
  • Gazi University Affiliated: Yes


Interdigitating dendritic cell tumor (IDCT) is an extremely rare malignancy. It occurs primarily in lymph nodes, but extranodal involvement has also been reported. A 38-year-old woman with IDCT with breast and cervical lymph-node involvement is reported in this paper. To our knowledge, this is the first case of IDCT originating from the breast. In the breast and lymph node, the tumor displayed diffuse sheets, fascicles and storiform growth pattern. It was composed of oval to spindle cells with pale to eosinophilic cytoplasm, ill-defined cell outlines, oval nuclei with vesicular chromatin and prominent eosinophilic nucleoli. Mitotic activity was three per ten high-power fields. The neoplastic cells were intermingled with small mature lymphocytes and plasma cells. Immunohistochemical studies showed that the tumor cells were strongly and diffusely positive for vimentin, CD68, S-100 protein, CD45/leukocyte common antigen and fascin and focally positive for lysozyme, alpha-1 antitrypsin and CD4. Ki-67 labeling index was 10%. The patient was treated with combined therapeutic approaches, including surgery, radiotherapy and chemotherapy. IDCT has the potential for an aggressive clinical course. However, 32 months after the initial diagnosis, the patient is still alive and being followed with a stable tumor burden.